NASDAQ:CVAC 10 August 2025 - 16 August 2025

For the period August 15–16, 2025, the biotech, pharma, medical, and health sectors saw a flurry of significant developments worldwide. Here is a comprehensive roundup of the top stories, categorized by theme and featuring expert insights and source links: Novo Nordisk’s blockbuster weight-loss drug Wegovy received accelerated approval from the U.S. FDA to treat metabolic dysfunction-associated steatohepatitis, a serious fatty liver disease reuters.com. This makes Wegovy the first GLP-1 class therapy cleared for MASH, an ailment affecting roughly 5% of U.S. adults reuters.com. The decision was based on part 1 of an ongoing trial showing Wegovy improved liver health and scarring in more patients than placebo reuters.com. “There really [have] not been good treatments in this space… we really need better medications that… prevent the progression of the disease,” said Jason Brett, Novo Nordisk’s U.S. medical chief reuters.com. Novo is pursuing approvals in Europe and Japan based on these interim results reuters.com, potentially strengthening its lead in metabolic diseases. Rival Eli Lilly’s tirzepatide has also shown promise in MASH in mid-stage trials reuters.com, underscoring the high-stakes race in this therapeutic area.